Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.

Tobias SchuppThomas BertschMarielen ReinhardtNoah AbelAlexander SchmittFelix LauMohammad AbumayyalehMuharrem AkinChristel WeißKathrin WeidnerMichael BehnesIbrahim Akin

Published in: European journal of preventive cardiology (2024)

Beta-blockers, ACEi/ARB/ARNI, and SGLT2i were independently associated with a lower risk of all-cause mortality in patients with HFmrEF, specifically when applied as combined 'HF triple therapy'. Randomized studies are needed to investigate the effect of HF-related pharmacotherapies in patients with HFmrEF.

Keyphrases

acute heart failure
heart failure
double blind
open label
placebo controlled
phase iii
angiotensin converting enzyme
phase ii
left ventricular
case control
clinical trial
atrial fibrillation
cardiac resynchronization therapy
stem cells
randomized controlled trial
bone marrow
cell therapy